This Biotech Stock Moves One Step Closer to an Alzheimer’s Drug; Analyst Says ‘Buy’

In the biotechnology world, clinical data readouts are make-or-break. Release favorable results, and rewards in the form of sky-high gains could be on tap, but if the data misses the mark, shares could also be catapulted, only in the opposite direction.Cassava Sciences (SAVA) is a prime example of the former. On Monday, the company published the final results from the Phase 2b study of sumifilam (PTI-125), its small molecule drug that targets an altered form of filamin A (FLNA), in mild-moderate Alzheimer’s disease (AD). The data demonstrated statistically significant improvements in biomarkers of disease and cognition. In response, shares rounded …read more

Source:: Yahoo Finance